{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:58:47Z","timestamp":1790276327183,"version":"4.1.0"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117416","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:45:57Z","timestamp":1789321557000},"page":"117416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Engineering next-generation CAR-T cells for glioblastoma treatment: a review of innovations in receptor design, antigen targeting, and therapeutic persistence"],"prefix":"10.1016","volume":"189","author":[{"given":"Aleksandra","family":"Kr\u00f3likowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Bia\u0142kowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117416_bb0005","doi-asserted-by":"crossref","unstructured":"S. Park, M. V. Maus, i B. D. Choi, \u201eCAR-T cell therapy for the treatment of adult high-grade gliomas\u201d, npj Precis. Oncol., t. 8, nr 1, s. 279, grud. 2024, doi:https:\/\/doi.org\/10.1038\/s41698-024-00753-0.","DOI":"10.1038\/s41698-024-00753-0"},{"key":"10.1016\/j.intimp.2026.117416_bb0010","doi-asserted-by":"crossref","unstructured":"A. G. Osborn, D. N. Louis, T. Y. Poussaint, L. L. Linscott, i K. L. Salzman, \u201eThe 2021 World Health Organization classification of tumors of the central nervous system: what neuroradiologists need to know\u201d, AJNR Am. J. Neuroradiol., t. 43, nr 7, s. 928\u2013937, lip. 2022, doi:https:\/\/doi.org\/10.3174\/ajnr.A7462.","DOI":"10.3174\/ajnr.A7462"},{"key":"10.1016\/j.intimp.2026.117416_bb0015","doi-asserted-by":"crossref","unstructured":"S. S. K. Yalamarty et al., \u201eMechanisms of resistance and current treatment options for glioblastoma multiforme (GBM)\u201d, Cancers, t. 15, nr 7, s. 2116, kwi. 2023, doi:https:\/\/doi.org\/10.3390\/cancers15072116.","DOI":"10.3390\/cancers15072116"},{"key":"10.1016\/j.intimp.2026.117416_bb0020","doi-asserted-by":"crossref","unstructured":"M. Montoya, M. Gallus, S. Phyu, J. Haegelin, J. De Groot, i H. Okada, \u201eA roadmap of CAR-T-cell therapy in glioblastoma: challenges and future perspectives\u201d, Cells, t. 13, nr 9, s. 726, kwi. 2024, doi:https:\/\/doi.org\/10.3390\/cells13090726.","DOI":"10.3390\/cells13090726"},{"key":"10.1016\/j.intimp.2026.117416_bb0025","doi-asserted-by":"crossref","unstructured":"A. S. Luksik, E. Yazigi, P. Shah, i C. M. Jackson, \u201eCAR T cell therapy in glioblastoma: overcoming challenges related to antigen expression\u201d, Cancers, t. 15, nr 5, s. 1414, lut. 2023, doi:https:\/\/doi.org\/10.3390\/cancers15051414.","DOI":"10.3390\/cancers15051414"},{"key":"10.1016\/j.intimp.2026.117416_bb0030","doi-asserted-by":"crossref","unstructured":"M. Fu, B. Xue, X. Miao, i Z. Gao, \u201eOvercoming immunotherapy resistance in glioblastoma: challenges and emerging strategies\u201d, Front. Pharmacol., t. 16, s. 1584688, mar. 2025, doi:https:\/\/doi.org\/10.3389\/fphar.2025.1584688.","DOI":"10.3389\/fphar.2025.1584688"},{"key":"10.1016\/j.intimp.2026.117416_bb0035","doi-asserted-by":"crossref","unstructured":"Z. Sarfraz, A. Maharaj, V. Venur, J. Lathia, Y. Odia, i M. Ahluwalia, \u201eImmunotherapy in glioblastoma: an overview of current status\u201d, CPAA, t. Volume 17, s. 185\u2013209, lip. 2025, doi:https:\/\/doi.org\/10.2147\/CPAA.S497903.","DOI":"10.2147\/CPAA.S497903"},{"key":"10.1016\/j.intimp.2026.117416_bb0040","doi-asserted-by":"crossref","unstructured":"C. Wang et al., \u201eGene targets of CAR-T cell therapy for glioblastoma\u201d, Cancers, t. 15, nr 8, s. 2351, kwi. 2023, doi:https:\/\/doi.org\/10.3390\/cancers15082351.","DOI":"10.3390\/cancers15082351"},{"key":"10.1016\/j.intimp.2026.117416_bb0045","doi-asserted-by":"crossref","unstructured":"S. L. Begley, D. M. O'Rourke, i Z. A. Binder, \u201eCAR T cell therapy for glioblastoma: a review of the first decade of clinical trials\u201d, Mol. Ther., t. 33, nr 6, s. 2454\u20132461, cze. 2025, doi:https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.004.","DOI":"10.1016\/j.ymthe.2025.03.004"},{"key":"10.1016\/j.intimp.2026.117416_bb0050","doi-asserted-by":"crossref","unstructured":"E. Agosti et al., \u201eCAR-T cells therapy in glioblastoma: a systematic review on molecular targets and treatment strategies\u201d, Int. J. Mol. Sci., t. 25, nr 13, s. 7174, cze. 2024, doi:https:\/\/doi.org\/10.3390\/ijms25137174.","DOI":"10.3390\/ijms25137174"},{"key":"10.1016\/j.intimp.2026.117416_bb0055","doi-asserted-by":"crossref","unstructured":"G. Escobar, T. R. Berger, i M. V. Maus, \u201eCAR-T cells in solid tumors: challenges and breakthroughs\u201d, Cell Rep. Med., s. 102353, wrz. 2025, doi:https:\/\/doi.org\/10.1016\/j.xcrm.2025.102353.","DOI":"10.1016\/j.xcrm.2025.102353"},{"key":"10.1016\/j.intimp.2026.117416_bb0060","doi-asserted-by":"crossref","unstructured":"Z. Liu et al., \u201eImmunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy\u201d, Theranostics, t. 12, nr 14, s. 6273\u20136290, 2022, doi:https:\/\/doi.org\/10.7150\/thno.76854.","DOI":"10.7150\/thno.76854"},{"key":"10.1016\/j.intimp.2026.117416_bb0065","doi-asserted-by":"crossref","unstructured":"M. A. Habibi et al., \u201eEnhancing T cell infiltration in glioblastoma: a review article on challenges and therapeutic strategies\u201d, Cancer Treat. Res. Commun., t. 45, s. 100999, 2025, doi:https:\/\/doi.org\/10.1016\/j.ctarc.2025.100999.","DOI":"10.1016\/j.ctarc.2025.100999"},{"key":"10.1016\/j.intimp.2026.117416_bb0070","doi-asserted-by":"crossref","unstructured":"D. Xu et al., \u201eThe development of CAR design for tumor CAR-T cell therapy\u201d, Oncotarget, t. 9, nr 17, s. 13991\u201314004, mar. 2018, doi:10.18632\/oncotarget.24179.","DOI":"10.18632\/oncotarget.24179"},{"key":"10.1016\/j.intimp.2026.117416_bb0075","doi-asserted-by":"crossref","unstructured":"R. C. Sterner i R. M. Sterner, \u201eCAR-T cell therapy: current limitations and potential strategies\u201d, Blood Cancer J., t. 11, nr 4, s. 69, kwi. 2021, doi:https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","DOI":"10.1038\/s41408-021-00459-7"},{"key":"10.1016\/j.intimp.2026.117416_bb0080","doi-asserted-by":"crossref","unstructured":"K. K. Patel, M. Tariveranmoshabad, S. Kadu, N. Shobaki, i C. June, \u201eFrom concept to cure: the evolution of CAR-T cell therapy\u201d, Mol. Ther., t. 33, nr 5, s. 2123\u20132140, maja 2025, doi:https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.005.","DOI":"10.1016\/j.ymthe.2025.03.005"},{"key":"10.1016\/j.intimp.2026.117416_bb0085","doi-asserted-by":"crossref","unstructured":"A. A. Alsaieedi i K. A. Zaher, \u201eTracing the development of CAR-T cell design: from concept to next-generation platforms\u201d, Front. Immunol., t. 16, s. 1615212, lip. 2025, doi:https:\/\/doi.org\/10.3389\/fimmu.2025.1615212.","DOI":"10.3389\/fimmu.2025.1615212"},{"key":"10.1016\/j.intimp.2026.117416_bb0090","doi-asserted-by":"crossref","unstructured":"J. Gallego-Valle et al., \u201eHigh specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-\u03b6) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy\u201d, Front. Immunol., t. 15, s. 1448752, wrz. 2024, doi:https:\/\/doi.org\/10.3389\/fimmu.2024.1448752.","DOI":"10.3389\/fimmu.2024.1448752"},{"key":"10.1016\/j.intimp.2026.117416_bb0095","doi-asserted-by":"crossref","unstructured":"M. Hiltensperger i A. M. Krackhardt, \u201eCurrent and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells\u201d, Front. Immunol., t. 14, s. 1121030, mar. 2023, doi:https:\/\/doi.org\/10.3389\/fimmu.2023.1121030.","DOI":"10.3389\/fimmu.2023.1121030"},{"key":"10.1016\/j.intimp.2026.117416_bb0100","doi-asserted-by":"crossref","unstructured":"T. Asmamaw Dejenie, M. Tiruneh G\/Medhin, G. Dessie Terefe, F. Tadele Admasu, W. Wale Tesega, i E. Chekol Abebe, \u201eCurrent updates on generations, approvals, and clinical trials of CAR T-cell therapy\u201d, Hum. Vaccin. Immunother., t. 18, nr 6, s. 2114254, lis. 2022, doi:https:\/\/doi.org\/10.1080\/21645515.2022.2114254.","DOI":"10.1080\/21645515.2022.2114254"},{"key":"10.1016\/j.intimp.2026.117416_bb0105","doi-asserted-by":"crossref","unstructured":"Y. Duan et al., \u201eTuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy\u201d, Cell. Mol. Life Sci., t. 79, nr 1, s. 14, sty. 2022, doi:https:\/\/doi.org\/10.1007\/s00018-021-04089-x.","DOI":"10.1007\/s00018-021-04089-x"},{"key":"10.1016\/j.intimp.2026.117416_bb0110","doi-asserted-by":"crossref","unstructured":"I. Zugasti et al., \u201eCAR-T cell therapy for cancer: current challenges and future directions\u201d, Sig. Transduct. Target Ther., t. 10, nr 1, s. 210, lip. 2025, doi:https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","DOI":"10.1038\/s41392-025-02269-w"},{"key":"10.1016\/j.intimp.2026.117416_bb0115","doi-asserted-by":"crossref","unstructured":"K. Ma i P. Hu, \u201eChimeric antigen receptor T-cell therapy for glioblastoma\u201d, Cancers, t. 15, nr 23, s. 5652, lis. 2023, doi:https:\/\/doi.org\/10.3390\/cancers15235652.","DOI":"10.3390\/cancers15235652"},{"key":"10.1016\/j.intimp.2026.117416_bb0120","doi-asserted-by":"crossref","unstructured":"L. T. Rodgers, J. L. Villano, A. M. S. Hartz, i B. Bauer, \u201eGlioblastoma standard of care: effects on tumor evolution and reverse translation in preclinical models\u201d, Cancers, t. 16, nr 15, s. 2638, lip. 2024, doi:https:\/\/doi.org\/10.3390\/cancers16152638.","DOI":"10.3390\/cancers16152638"},{"key":"10.1016\/j.intimp.2026.117416_bb0125","doi-asserted-by":"crossref","unstructured":"Y. Hu, X. Ge, Q. Xie, R. Ma, i Q. Tao, \u201eProgress in the study of molecular markers in the prognosis assessment and recurrence patterns of glioblastoma\u201d, Cancer Biol. Ther. 26, nr 1, s. 2574179, grud. 2025, doi:https:\/\/doi.org\/10.1080\/15384047.2025.2574179.","DOI":"10.1080\/15384047.2025.2574179"},{"key":"10.1016\/j.intimp.2026.117416_bb0130","doi-asserted-by":"crossref","unstructured":"C. M. Walton et al., \u201eChimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions\u201d, J. Immunother. Cancer, t. 13, nr 10, s. e012308, lis. 2025, doi:https:\/\/doi.org\/10.1136\/jitc-2025-012308.","DOI":"10.1136\/jitc-2025-012308"},{"key":"10.1016\/j.intimp.2026.117416_bb0135","series-title":"CART-EGFRvIII + Pembrolizumab in GBM","author":"University of Pennsylvania","year":"2026"},{"key":"10.1016\/j.intimp.2026.117416_bb0140","doi-asserted-by":"crossref","unstructured":"J. T. N. Chan, J. Henley-Waters, i S. Kayhanian, \u201eChimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review\u201d, Neuro-Oncol. Adv., t. 7, nr 1, s. vdaf115, sty. 2025, doi:https:\/\/doi.org\/10.1093\/noajnl\/vdaf115.","DOI":"10.1093\/noajnl\/vdaf115"},{"key":"10.1016\/j.intimp.2026.117416_bb0145","unstructured":"City of Hope Medical Center, \u201eGenetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma\u201d, ClinicalTrials.gov, NCT02208362. Dost\u0119p: 11 lutego 2026. [Online]. Dost\u0119pne na: https:\/\/clinicaltrials.gov\/study\/NCT02208362."},{"key":"10.1016\/j.intimp.2026.117416_bb0150","doi-asserted-by":"crossref","unstructured":"M. S. Ansari et al., \u201eAI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape\u201d, Nat. Commun., t. 17, nr 1, s. 1549, sty. 2026, doi:https:\/\/doi.org\/10.1038\/s41467-025-68272-5.","DOI":"10.1038\/s41467-025-68272-5"},{"key":"10.1016\/j.intimp.2026.117416_bb0155","doi-asserted-by":"crossref","unstructured":"A. Schmidts et al., \u201eTandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma\u201d, Neuro-Oncol. Adv., t. 5, nr 1, s. vdac185, sty. 2023, doi:https:\/\/doi.org\/10.1093\/noajnl\/vdac185.","DOI":"10.1093\/noajnl\/vdac185"},{"key":"10.1016\/j.intimp.2026.117416_bb0160","doi-asserted-by":"crossref","unstructured":"S. I. Choi i J. Yin, \u201eProspective approaches to enhancing CAR T cell therapy for glioblastoma\u201d, Front. Immunol., t. 13, s. 1008751, pa\u017a. 2022, doi:https:\/\/doi.org\/10.3389\/fimmu.2022.1008751.","DOI":"10.3389\/fimmu.2022.1008751"},{"key":"10.1016\/j.intimp.2026.117416_bb0165","doi-asserted-by":"crossref","unstructured":"V. Zoi, V. Galani, C. Sioka, G. A. Alexiou, i A. P. Kyritsis, \u201eImmunotherapy for glioblastoma: a focus on PD-1\/PD-L1 inhibitors\u201d, Cancers, t. 17, nr 23, s. 3777, lis. 2025, doi:https:\/\/doi.org\/10.3390\/cancers17233777.","DOI":"10.3390\/cancers17233777"},{"key":"10.1016\/j.intimp.2026.117416_bb0170","doi-asserted-by":"crossref","unstructured":"P. M. Nanjireddy, S. H. Olejniczak, i N. P. Buxbaum, \u201eTargeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes\u201d, Front. Immunol., t. 14, s. 1121565, mar. 2023, doi:https:\/\/doi.org\/10.3389\/fimmu.2023.1121565.","DOI":"10.3389\/fimmu.2023.1121565"},{"key":"10.1016\/j.intimp.2026.117416_bb0175","doi-asserted-by":"crossref","unstructured":"A. Van Der Vreken, K. Vanderkerken, E. De Bruyne, K. De Veirman, K. Breckpot, i E. Menu, \u201eFueling CARs: metabolic strategies to enhance CAR T-cell therapy\u201d, Exp. Hematol. Oncol., t. 13, nr 1, s. 66, lip. 2024, doi:https:\/\/doi.org\/10.1186\/s40164-024-00535-1.","DOI":"10.1186\/s40164-024-00535-1"},{"key":"10.1016\/j.intimp.2026.117416_bb0180","doi-asserted-by":"crossref","unstructured":"M. B. Watowich, M. R. Gilbert, i M. Larion, \u201eT cell exhaustion in malignant gliomas\u201d, Trends Cancer, t. 9, nr 4, s. 270\u2013292, kwi. 2023, doi:https:\/\/doi.org\/10.1016\/j.trecan.2022.12.008.","DOI":"10.1016\/j.trecan.2022.12.008"},{"key":"10.1016\/j.intimp.2026.117416_bb0185","doi-asserted-by":"crossref","unstructured":"N. E. Scharping et al., \u201eMitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion\u201d, Nat. Immunol., t. 22, nr 2, s. 205\u2013215, lut. 2021, doi:https:\/\/doi.org\/10.1038\/s41590-020-00834-9.","DOI":"10.1038\/s41590-020-00834-9"},{"key":"10.1016\/j.intimp.2026.117416_bb0190","doi-asserted-by":"crossref","unstructured":"B. Bengsch et al., \u201eBioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8 + T cell exhaustion\u201d, Immunity, t. 45, nr 2, s. 358\u2013373, sie. 2016, doi:https:\/\/doi.org\/10.1016\/j.immuni.2016.07.008.","DOI":"10.1016\/j.immuni.2016.07.008"},{"key":"10.1016\/j.intimp.2026.117416_bb0195","doi-asserted-by":"crossref","unstructured":"H. Wu et al., \u201eMitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1\u03b1-mediated glycolytic reprogramming\u201d, Nat. Commun., t. 14, nr 1, s. 6858, pa\u017a. 2023, doi:https:\/\/doi.org\/10.1038\/s41467-023-42634-3.","DOI":"10.1038\/s41467-023-42634-3"},{"key":"10.1016\/j.intimp.2026.117416_bb0200","doi-asserted-by":"crossref","unstructured":"O. Khan et al., \u201eTOX transcriptionally and epigenetically programs CD8+ T cell exhaustion\u201d, Nature, t. 571, nr 7764, s. 211\u2013218, lip. 2019, doi:https:\/\/doi.org\/10.1038\/s41586-019-1325-x.","DOI":"10.1038\/s41586-019-1325-x"},{"key":"10.1016\/j.intimp.2026.117416_bb0205","doi-asserted-by":"crossref","unstructured":"H. Seo et al., \u201eTOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion\u201d, Proc. Natl. Acad. Sci. USA, t. 116, nr 25, s. 12410\u201312415, cze. 2019, doi:https:\/\/doi.org\/10.1073\/pnas.1905675116.","DOI":"10.1073\/pnas.1905675116"},{"key":"10.1016\/j.intimp.2026.117416_bb0210","doi-asserted-by":"crossref","unstructured":"J. Chen et al., \u201eNR4A transcription factors limit CAR T cell function in solid tumours\u201d, Nature, t. 567, nr 7749, s. 530\u2013534, mar. 2019, doi:https:\/\/doi.org\/10.1038\/s41586-019-0985-x.","DOI":"10.1038\/s41586-019-0985-x"},{"key":"10.1016\/j.intimp.2026.117416_bb0215","doi-asserted-by":"crossref","unstructured":"D. R. Sen et al., \u201eThe epigenetic landscape of T cell exhaustion\u201d, Science, t. 354, nr 6316, s. 1165\u20131169, grud. 2016, doi:https:\/\/doi.org\/10.1126\/science.aae0491.","DOI":"10.1126\/science.aae0491"},{"key":"10.1016\/j.intimp.2026.117416_bb0220","doi-asserted-by":"crossref","unstructured":"J.-C. Beltra et al., \u201eDevelopmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms\u201d, Immunity, t. 52, nr 5, s. 825-841.e8, maja 2020, doi:https:\/\/doi.org\/10.1016\/j.immuni.2020.04.014.","DOI":"10.1016\/j.immuni.2020.04.014"},{"key":"10.1016\/j.intimp.2026.117416_bb0225","doi-asserted-by":"crossref","unstructured":"D. T. Utzschneider et al., \u201eT cell factor 1-expressing memory-like CD8+ T cells sustain the immune response to chronic viral infections\u201d, Immunity, t. 45, nr 2, s. 415\u2013427, sie. 2016, doi:https:\/\/doi.org\/10.1016\/j.immuni.2016.07.021.","DOI":"10.1016\/j.immuni.2016.07.021"},{"key":"10.1016\/j.intimp.2026.117416_bb0230","doi-asserted-by":"crossref","unstructured":"A. Holtermann et al., \u201eProspects of synergy: local interventions and CAR T cell therapy in solid tumors\u201d, BioDrugs, t. 38, nr 5, s. 611\u2013637, wrz. 2024, doi:https:\/\/doi.org\/10.1007\/s40259-024-00669-y.","DOI":"10.1007\/s40259-024-00669-y"},{"key":"10.1016\/j.intimp.2026.117416_bb0235","doi-asserted-by":"crossref","unstructured":"Y. Durga i R. Pusapati, \u201eDrug resistance in glioblastoma: challenges, mechanisms and therapeutic strategies (review)\u201d, Mol. Clin. Oncol., t. 24, nr 1, s. 1\u201317, lis. 2025, doi:https:\/\/doi.org\/10.3892\/mco.2025.2913.","DOI":"10.3892\/mco.2025.2913"},{"key":"10.1016\/j.intimp.2026.117416_bb0240","doi-asserted-by":"crossref","unstructured":"B. Bhutani, V. Sharma, N. K. Ganguly, i R. Rana, \u201eUnravelling the modified T cell receptor through gen-next CAR T cell therapy in glioblastoma: current status and future challenges\u201d, Biomed. Pharmacother., t. 186, s. 117987, maja 2025, doi:https:\/\/doi.org\/10.1016\/j.biopha.2025.117987.","DOI":"10.1016\/j.biopha.2025.117987"},{"key":"10.1016\/j.intimp.2026.117416_bb0245","doi-asserted-by":"crossref","unstructured":"R. D. Salinas, J. S. Durgin, i D. M. O'Rourke, \u201ePotential of glioblastoma-targeted chimeric antigen receptor (CAR) T-cell therapy\u201d, CNS Drugs, t. 34, nr 2, s. 127\u2013145, lut. 2020, doi:https:\/\/doi.org\/10.1007\/s40263-019-00687-3.","DOI":"10.1007\/s40263-019-00687-3"},{"key":"10.1016\/j.intimp.2026.117416_bb0250","doi-asserted-by":"crossref","unstructured":"R. K. Sarma, P. Nath, P. Bora, P. Chetia, i A. Bala, \u201eAdvancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: navigating the current landscape from clinical hurdles to breakthrough strategies\u201d, Int. Immunopharmacol., t. 187, s. 117134, pa\u017a. 2026, doi:https:\/\/doi.org\/10.1016\/j.intimp.2026.117134.","DOI":"10.1016\/j.intimp.2026.117134"},{"key":"10.1016\/j.intimp.2026.117416_bb0255","doi-asserted-by":"crossref","unstructured":"J. Jayaraman et al., \u201eCAR-T design: elements and their synergistic function\u201d, EBioMedicine, t. 58, s. 102931, sie. 2020, doi:https:\/\/doi.org\/10.1016\/j.ebiom.2020.102931.","DOI":"10.1016\/j.ebiom.2020.102931"},{"key":"10.1016\/j.intimp.2026.117416_bb0260","doi-asserted-by":"crossref","unstructured":"M. Cazaux et al., \u201eSingle-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity\u201d, J. Exp. Med., t. 216, nr 5, s. 1038\u20131049, maja 2019, doi:https:\/\/doi.org\/10.1084\/jem.20182375.","DOI":"10.1084\/jem.20182375"},{"key":"10.1016\/j.intimp.2026.117416_bb0265","doi-asserted-by":"crossref","unstructured":"M. J. Montalvo et al., \u201eDecoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition\u201d, Cell Death Dis., t. 15, nr 2, s. 109, lut. 2024, doi:https:\/\/doi.org\/10.1038\/s41419-024-06461-8.","DOI":"10.1038\/s41419-024-06461-8"},{"key":"10.1016\/j.intimp.2026.117416_bb0270","doi-asserted-by":"crossref","unstructured":"M. V. Maus, \u201eSignatures of dysfunctional CAR T cells\u201d, Blood, t. 141, nr 26, s. 3127\u20133129, cze. 2023, doi:https:\/\/doi.org\/10.1182\/blood.2023020935.","DOI":"10.1182\/blood.2023020935"},{"key":"10.1016\/j.intimp.2026.117416_bb0275","doi-asserted-by":"crossref","unstructured":"Y. Kagoya et al., \u201eA novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects\u201d, Nat. Med., t. 24, nr 3, s. 352\u2013359, mar. 2018, doi:https:\/\/doi.org\/10.1038\/nm.4478.","DOI":"10.1038\/nm.4478"},{"key":"10.1016\/j.intimp.2026.117416_bb0280","doi-asserted-by":"crossref","unstructured":"J. Tomasik, M. Jasi\u0144ski, i G. W. Basak, \u201eNext generations of CAR-T cells - new therapeutic opportunities in hematology?\u201d, Front. Immunol., t. 13, s. 1034707, pa\u017a. 2022, doi:https:\/\/doi.org\/10.3389\/fimmu.2022.1034707.","DOI":"10.3389\/fimmu.2022.1034707"},{"key":"10.1016\/j.intimp.2026.117416_bb0285","doi-asserted-by":"crossref","unstructured":"K. S. Rallis, C. R. T. Hillyar, M. Sideris, i J. K. Davies, \u201eT-cell-based immunotherapies for haematological cancers, part B: a SWOT analysis of adoptive cell therapies\u201d, Anticancer Res., t. 41, nr 3, s. 1143\u20131156, mar. 2021, doi:10.21873\/anticanres.14871.","DOI":"10.21873\/anticanres.14871"},{"key":"10.1016\/j.intimp.2026.117416_bb0290","doi-asserted-by":"crossref","unstructured":"S. E. Lindner, S. M. Johnson, C. E. Brown, i L. D. Wang, \u201eChimeric antigen receptor signaling: functional consequences and design implications\u201d, Sci. Adv., t. 6, nr 21, s. eaaz3223, maja 2020, doi:https:\/\/doi.org\/10.1126\/sciadv.aaz3223.","DOI":"10.1126\/sciadv.aaz3223"},{"key":"10.1016\/j.intimp.2026.117416_bb0295","doi-asserted-by":"crossref","unstructured":"L. Alabanza et al., \u201eFunction of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains\u201d, Mol. Ther., t. 25, nr 11, s. 2452\u20132465, lis. 2017, doi:https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.013.","DOI":"10.1016\/j.ymthe.2017.07.013"},{"key":"10.1016\/j.intimp.2026.117416_bb0300","doi-asserted-by":"crossref","unstructured":"G. Li et al., \u201e4-1BB enhancement of CAR T function requires NF-\u03baB and TRAFs\u201d, JCI Insight, t. 3, nr 18, s. e121322, wrz. 2018, doi:https:\/\/doi.org\/10.1172\/jci.insight.121322.","DOI":"10.1172\/jci.insight.121322"},{"key":"10.1016\/j.intimp.2026.117416_bb0305","doi-asserted-by":"crossref","unstructured":"A. I. Salter et al., \u201ePhosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function\u201d, Sci. Signal., t. 11, nr 544, s. eaat6753, sie. 2018, doi:https:\/\/doi.org\/10.1126\/scisignal.aat6753.","DOI":"10.1126\/scisignal.aat6753"},{"key":"10.1016\/j.intimp.2026.117416_bb0310","doi-asserted-by":"crossref","unstructured":"O. U. Kawalekar et al., \u201eDistinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells\u201d, Immunity, t. 44, nr 2, s. 380\u2013390, lut. 2016, doi:https:\/\/doi.org\/10.1016\/j.immuni.2016.01.021.","DOI":"10.1016\/j.immuni.2016.01.021"},{"key":"10.1016\/j.intimp.2026.117416_bb0315","doi-asserted-by":"crossref","unstructured":"C. Sun et al., \u201eTHEMIS-SHP1 recruitment by 4-1BB tunes LCK-mediated priming of chimeric antigen receptor-redirected T cells\u201d, Cancer Cell, t. 37, nr 2, s. 216-225.e6, lut. 2020, doi:https:\/\/doi.org\/10.1016\/j.ccell.2019.12.014.","DOI":"10.1016\/j.ccell.2019.12.014"},{"key":"10.1016\/j.intimp.2026.117416_bb0320","doi-asserted-by":"crossref","unstructured":"A. H. Long et al., \u201e4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors\u201d, Nat. Med., t. 21, nr 6, s. 581\u2013590, cze. 2015, doi:https:\/\/doi.org\/10.1038\/nm.3838.","DOI":"10.1038\/nm.3838"},{"key":"10.1016\/j.intimp.2026.117416_bb0325","doi-asserted-by":"crossref","unstructured":"D. Gomes-Silva et al., \u201eTonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent\u201d, Cell Rep., t. 21, nr 1, s. 17\u201326, pa\u017a. 2017, doi:https:\/\/doi.org\/10.1016\/j.celrep.2017.09.015.","DOI":"10.1016\/j.celrep.2017.09.015"},{"key":"10.1016\/j.intimp.2026.117416_bb0330","doi-asserted-by":"crossref","unstructured":"D. Shukla et al., \u201eCAR binders affect CAR T-cell tonic signaling, durability, and sensitivity to target\u201d, Cancer Immunol. Res., t. 13, nr 6, s. 867\u2013880, cze. 2025, doi:https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-1347.","DOI":"10.1158\/2326-6066.CIR-24-1347"},{"key":"10.1016\/j.intimp.2026.117416_bb0335","doi-asserted-by":"crossref","unstructured":"Yerevan Mkhitar Heratsi State Medical University, Yerevan, Armenia i M. Tavadyan, Engineering CAR and TCR T-cells to overcome resistance in Cancer therapy\u201d, ODMJ, 2025, doi:10.69690\/ODMJ-002-1119-6002.","DOI":"10.69690\/ODMJ-002-1119-6002"},{"key":"10.1016\/j.intimp.2026.117416_bb0340","doi-asserted-by":"crossref","unstructured":"J. Feucht et al., \u201eCalibration of CAR activation potential directs alternative T cell fates and therapeutic potency\u201d, Nat. Med., t. 25, nr 1, s. 82\u201388, sty. 2019, doi:https:\/\/doi.org\/10.1038\/s41591-018-0290-5.","DOI":"10.1038\/s41591-018-0290-5"},{"key":"10.1016\/j.intimp.2026.117416_bb0345","doi-asserted-by":"crossref","unstructured":"R. Starr et al., \u201eInclusion of 4-1BB costimulation enhances selectivity and functionality of IL13R\u03b12-targeted chimeric antigen receptor T cells\u201d, Cancer Res. Commun., t. 3, nr 1, s. 66\u201379, sty. 2023, doi:https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0185.","DOI":"10.1158\/2767-9764.CRC-22-0185"},{"key":"10.1016\/j.intimp.2026.117416_bb0350","doi-asserted-by":"crossref","unstructured":"J. H. Choe et al., \u201eSynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma\u201d, Sci. Transl. Med., t. 13, nr 591, s. eabe7378, kwi. 2021, doi:https:\/\/doi.org\/10.1126\/scitranslmed.abe7378.","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"10.1016\/j.intimp.2026.117416_bb0355","doi-asserted-by":"crossref","unstructured":"Z. L. Z. Hay i J. E. Slansky, \u201eGranzymes: the molecular executors of immune-mediated cytotoxicity\u201d, Int. J. Mol. Sci., t. 23, nr 3, s. 1833, lut. 2022, doi:https:\/\/doi.org\/10.3390\/ijms23031833.","DOI":"10.3390\/ijms23031833"},{"key":"10.1016\/j.intimp.2026.117416_bb0360","doi-asserted-by":"crossref","unstructured":"T. Huan et al., \u201eActivation-induced cell death in CAR-T cell therapy\u201d, Hum. Cell, t. 35, nr 2, s. 441\u2013447, mar. 2022, doi:https:\/\/doi.org\/10.1007\/s13577-022-00670-z.","DOI":"10.1007\/s13577-022-00670-z"},{"key":"10.1016\/j.intimp.2026.117416_bb0365","doi-asserted-by":"crossref","unstructured":"A. J. Freeman, C. J. Kearney, J. Silke, i J. Oliaro, \u201eUnleashing TNF cytotoxicity to enhance cancer immunotherapy\u201d, Trends Immunol., t. 42, nr 12, s. 1128\u20131142, grud. 2021, doi:https:\/\/doi.org\/10.1016\/j.it.2021.10.003.","DOI":"10.1016\/j.it.2021.10.003"},{"key":"10.1016\/j.intimp.2026.117416_bb0370","doi-asserted-by":"crossref","unstructured":"M. Bell i S. Gottschalk, \u201eEngineered cytokine signaling to improve CAR T cell effector function\u201d, Front. Immunol., t. 12, s. 684642, cze. 2021, doi:https:\/\/doi.org\/10.3389\/fimmu.2021.684642.","DOI":"10.3389\/fimmu.2021.684642"},{"key":"10.1016\/j.intimp.2026.117416_bb0375","doi-asserted-by":"crossref","unstructured":"L. J. B. Brandt, M. B. Barnkob, Y. S. Michaels, J. Heiselberg, i T. Barington, \u201eEmerging approaches for regulation and control of CAR T cells: a mini review\u201d, Front. Immunol., t. 11, s. 326, lut. 2020, doi:https:\/\/doi.org\/10.3389\/fimmu.2020.00326.","DOI":"10.3389\/fimmu.2020.00326"},{"key":"10.1016\/j.intimp.2026.117416_bb0380","doi-asserted-by":"crossref","unstructured":"S. Smirnov, P. Mateikovich, K. Samochernykh, i E. Shlyakhto, \u201eRecent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic\u201d, Front. Immunol., t. 15, s. 1335424, lut. 2024, doi:https:\/\/doi.org\/10.3389\/fimmu.2024.1335424.","DOI":"10.3389\/fimmu.2024.1335424"},{"key":"10.1016\/j.intimp.2026.117416_bb0385","doi-asserted-by":"crossref","unstructured":"W.-Y. Zhang, L.-Y. Yang, i X.-X. Fan, \u201eCAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies\u201d, Front. Immunol., t. 16, s. 1622433, lip. 2025, doi:https:\/\/doi.org\/10.3389\/fimmu.2025.1622433.","DOI":"10.3389\/fimmu.2025.1622433"},{"key":"10.1016\/j.intimp.2026.117416_bb0390","doi-asserted-by":"crossref","unstructured":"A. W. Li et al., \u201eEngineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation\u201d, Sci. Rep., t. 14, nr 1, s. 21331, wrz. 2024, doi:https:\/\/doi.org\/10.1038\/s41598-024-72392-1.","DOI":"10.1038\/s41598-024-72392-1"},{"key":"10.1016\/j.intimp.2026.117416_bb0395","doi-asserted-by":"crossref","unstructured":"R. Huang et al., \u201eRecent advances in CAR-T cell engineering\u201d, J. Hematol. Oncol., t. 13, nr 1, s. 86, grud. 2020, doi:https:\/\/doi.org\/10.1186\/s13045-020-00910-5.","DOI":"10.1186\/s13045-020-00910-5"},{"key":"10.1016\/j.intimp.2026.117416_bb0400","doi-asserted-by":"crossref","unstructured":"Y. Su et al., \u201eEnhancement of CAR-T cell efficacy and persistence via CD30 costimulation and NF-\u03baB signaling\u201d, Mol. Cancer, t. 24, nr 1, s. 289, lis. 2025, doi:https:\/\/doi.org\/10.1186\/s12943-025-02446-z.","DOI":"10.1186\/s12943-025-02446-z"},{"key":"10.1016\/j.intimp.2026.117416_bb0405","doi-asserted-by":"crossref","unstructured":"I. Andreu-Saumell et al., \u201eCAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition\u201d, Nat. Commun., t. 15, nr 1, s. 3552, kwi. 2024, doi:https:\/\/doi.org\/10.1038\/s41467-024-47799-z.","DOI":"10.1038\/s41467-024-47799-z"},{"key":"10.1016\/j.intimp.2026.117416_bb0410","doi-asserted-by":"crossref","unstructured":"D. Landi et al., \u201eA checkpoint reversal receptor mediates bipartite activation and enhances CAR T-cell function\u201d, Cancer Res. Commun., t. 5, nr 3, s. 527\u2013548, mar. 2025, doi:https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0125.","DOI":"10.1158\/2767-9764.CRC-24-0125"},{"key":"10.1016\/j.intimp.2026.117416_bb0415","doi-asserted-by":"crossref","unstructured":"D. Xiong, H. Yu, i Z.-J. Sun, \u201eUnlocking T cell exhaustion: insights and implications for CAR-T cell therapy\u201d, Acta Pharm. Sin. B, t. 14, nr 8, s. 3416\u20133431, sie. 2024, doi:https:\/\/doi.org\/10.1016\/j.apsb.2024.04.022.","DOI":"10.1016\/j.apsb.2024.04.022"},{"key":"10.1016\/j.intimp.2026.117416_bb0420","doi-asserted-by":"crossref","unstructured":"Y. Zhou, F. Shi, J. Zhu, i Y. Yuan, \u201eAn update on the clinical trial research of immunotherapy for glioblastoma\u201d, Front. Immunol., t. 16, s. 1582296, maja 2025, doi:https:\/\/doi.org\/10.3389\/fimmu.2025.1582296.","DOI":"10.3389\/fimmu.2025.1582296"},{"key":"10.1016\/j.intimp.2026.117416_bb0425","doi-asserted-by":"crossref","unstructured":"M. A. Mansour et al., \u201eUnlocking the code: the role of molecular and genetic profiling in revolutionizing glioblastoma treatment\u201d, Cancer Treat. Res. Commun., t. 43, s. 100881, 2025, doi:https:\/\/doi.org\/10.1016\/j.ctarc.2025.100881.","DOI":"10.1016\/j.ctarc.2025.100881"},{"key":"10.1016\/j.intimp.2026.117416_bb0430","series-title":"CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM)","author":"Baylor College of Medicine","year":"2026"},{"key":"10.1016\/j.intimp.2026.117416_bb0435","doi-asserted-by":"crossref","unstructured":"R. A. Redondo-Frutos et al., \u201eGenetic engineering in CAR T cells for solid tumors: current state, barriers and future developments\u201d, Hum. Gene Ther., t. 36, nr 17\u201318, s. 1138\u20131153, wrz. 2025, doi:https:\/\/doi.org\/10.1177\/10430342251372041.","DOI":"10.1177\/10430342251372041"},{"key":"10.1016\/j.intimp.2026.117416_bb0440","doi-asserted-by":"crossref","unstructured":"R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, i S. A. Rosenberg, \u201eCase report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2\u201d, Mol. Ther., t. 18, nr 4, s. 843\u2013851, kwi. 2010, doi:https:\/\/doi.org\/10.1038\/mt.2010.24.","DOI":"10.1038\/mt.2010.24"},{"key":"10.1016\/j.intimp.2026.117416_bb0445","doi-asserted-by":"crossref","unstructured":"T. Inthanachai et al., \u201eNovel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study\u201d, J. Immunother. Cancer, t. 13, nr 1, s. e010083, sty. 2025, doi:https:\/\/doi.org\/10.1136\/jitc-2024-010083.","DOI":"10.1136\/jitc-2024-010083"},{"key":"10.1016\/j.intimp.2026.117416_bb0450","series-title":"Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM (CAR.B7-H3Tc)","author":"UNC Lineberger Comprehensive Cancer Center","year":"2026"},{"key":"10.1016\/j.intimp.2026.117416_bb0455","doi-asserted-by":"crossref","unstructured":"Y. Rauf et al., \u201eCTIM-32. Safety and tolerability of intraventricular infusion of B7-H3.CAR-T cells in recurrent glioblastoma\u201d, Neuro-Oncology, t. 27, nr Supplement_5, s. v121\u2013v122, lis. 2025, doi:https:\/\/doi.org\/10.1093\/neuonc\/noaf201.0489.","DOI":"10.1093\/neuonc\/noaf201.0489"},{"key":"10.1016\/j.intimp.2026.117416_bb0460","doi-asserted-by":"crossref","unstructured":"F. Kontos et al., \u201eB7-H3: an attractive target for antibody-based immunotherapy\u201d, Clin. Cancer Res., t. 27, nr 5, s. 1227\u20131235, mar. 2021, doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2584.","DOI":"10.1158\/1078-0432.CCR-20-2584"},{"key":"10.1016\/j.intimp.2026.117416_bb0465","doi-asserted-by":"crossref","unstructured":"F. Meeus et al., \u201ePreclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity\u201d, J. Immunother. Cancer, t. 12, nr 11, s. e009110, lis. 2024, doi:https:\/\/doi.org\/10.1136\/jitc-2024-009110.","DOI":"10.1136\/jitc-2024-009110"},{"key":"10.1016\/j.intimp.2026.117416_bb0470","doi-asserted-by":"crossref","unstructured":"H. Du et al., \u201eAntitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells\u201d, Cancer Cell, t. 35, nr 2, s. 221-237.e8, lut. 2019, doi:https:\/\/doi.org\/10.1016\/j.ccell.2019.01.002.","DOI":"10.1016\/j.ccell.2019.01.002"},{"key":"10.1016\/j.intimp.2026.117416_bb0475","doi-asserted-by":"crossref","unstructured":"R. G. Majzner et al., \u201eGD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas\u201d, Nature, t. 603, nr 7903, s. 934\u2013941, mar. 2022, doi:https:\/\/doi.org\/10.1038\/s41586-022-04489-4.","DOI":"10.1038\/s41586-022-04489-4"},{"key":"10.1016\/j.intimp.2026.117416_bb0480","doi-asserted-by":"crossref","unstructured":"Q. Lin et al., \u201eFirst-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose\u201d, Front. Oncol., t. 11, s. 694941, cze. 2021, doi:https:\/\/doi.org\/10.3389\/fonc.2021.694941.","DOI":"10.3389\/fonc.2021.694941"},{"key":"10.1016\/j.intimp.2026.117416_bb0485","series-title":"Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas","author":"Xuanwu Hospital, Beijing","year":"2026"},{"key":"10.1016\/j.intimp.2026.117416_bb0490","doi-asserted-by":"crossref","unstructured":"S. J. Bagley et al., \u201eIntracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial\u201d, Nat. Med., t. 31, nr 8, s. 2778\u20132787, sie. 2025, doi:https:\/\/doi.org\/10.1038\/s41591-025-03745-0.","DOI":"10.1038\/s41591-025-03745-0"},{"key":"10.1016\/j.intimp.2026.117416_bb0495","series-title":"CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM","year":"2026"},{"key":"10.1016\/j.intimp.2026.117416_bb0500","doi-asserted-by":"crossref","unstructured":"D. M. O'Rourke et al., \u201eA single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma\u201d, Sci. Transl. Med., t. 9, nr 399, s. eaaa0984, lip. 2017, doi:https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"10.1016\/j.intimp.2026.117416_bb0505","doi-asserted-by":"crossref","unstructured":"J. Felsberg et al., \u201eEpidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR -amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors\u201d, Clin. Cancer Res., t. 23, nr 22, s. 6846\u20136855, lis. 2017, doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0890.","DOI":"10.1158\/1078-0432.CCR-17-0890"},{"key":"10.1016\/j.intimp.2026.117416_bb0510","doi-asserted-by":"crossref","unstructured":"C. E. Brown et al., \u201eBioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma\u201d, Clin. Cancer Res., t. 21, nr 18, s. 4062\u20134072, wrz. 2015, doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0428.","DOI":"10.1158\/1078-0432.CCR-15-0428"},{"key":"10.1016\/j.intimp.2026.117416_bb0515","doi-asserted-by":"crossref","unstructured":"J. S. Jarboe, K. R. Johnson, Y. Choi, R. R. Lonser, i J. K. Park, \u201eExpression of Interleukin-13 receptor \u03b12 in glioblastoma multiforme: implications for targeted therapies\u201d, Cancer Res., t. 67, nr 17, s. 7983\u20137986, wrz. 2007, doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1493.","DOI":"10.1158\/0008-5472.CAN-07-1493"},{"key":"10.1016\/j.intimp.2026.117416_bb0520","doi-asserted-by":"crossref","unstructured":"M. Hegde et al., \u201eTandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape\u201d, J. Clin. Invest., t. 126, nr 8, s. 3036\u20133052, lip. 2016, doi:https:\/\/doi.org\/10.1172\/JCI83416.","DOI":"10.1172\/JCI83416"},{"key":"10.1016\/j.intimp.2026.117416_bb0525","doi-asserted-by":"crossref","unstructured":"D. Nehama et al., \u201eB7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres\u201d, EBioMedicine, t. 47, s. 33\u201343, wrz. 2019, doi:https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.030.","DOI":"10.1016\/j.ebiom.2019.08.030"},{"key":"10.1016\/j.intimp.2026.117416_bb0530","doi-asserted-by":"crossref","unstructured":"Z. Liu et al., \u201eSafety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma\u201d, Mol. Cancer, t. 22, nr 1, s. 3, sty. 2023, doi:https:\/\/doi.org\/10.1186\/s12943-022-01711-9.","DOI":"10.1186\/s12943-022-01711-9"},{"key":"10.1016\/j.intimp.2026.117416_bb0535","doi-asserted-by":"crossref","unstructured":"K. K. Chow et al., \u201eT cells redirected to EphA2 for the immunotherapy of glioblastoma\u201d, Mol. Ther., t. 21, nr 3, s. 629\u2013637, mar. 2013, doi:https:\/\/doi.org\/10.1038\/mt.2012.210.","DOI":"10.1038\/mt.2012.210"},{"key":"10.1016\/j.intimp.2026.117416_bb0540","doi-asserted-by":"crossref","unstructured":"Z. Yi, B. L. Prinzing, F. Cao, S. Gottschalk, i G. Krenciute, \u201eOptimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma\u201d, Mol. Ther. Methods Clin. Dev., t. 9, s. 70\u201380, cze. 2018, doi:https:\/\/doi.org\/10.1016\/j.omtm.2018.01.009.","DOI":"10.1016\/j.omtm.2018.01.009"},{"key":"10.1016\/j.intimp.2026.117416_bb0545","doi-asserted-by":"crossref","unstructured":"A. Mariniello i D. Migliorini, \u201eCAR-T cell therapies are coming after glioblastoma: an overview of early phase clinical trials and future perspectives\u201d, iScience, t. 29, nr 2, s. 114609, lut. 2026, doi:https:\/\/doi.org\/10.1016\/j.isci.2025.114609.","DOI":"10.1016\/j.isci.2025.114609"},{"key":"10.1016\/j.intimp.2026.117416_bb0550","doi-asserted-by":"crossref","unstructured":"C. Bao et al., \u201eThe application of nanobody in CAR-T therapy\u201d, Biomolecules, t. 11, nr 2, s. 238, lut. 2021, doi:https:\/\/doi.org\/10.3390\/biom11020238.","DOI":"10.3390\/biom11020238"},{"key":"10.1016\/j.intimp.2026.117416_bb0555","doi-asserted-by":"crossref","unstructured":"H. Liu et al., \u201eApplication of nanobody-based CAR-T in tumor immunotherapy (review)\u201d, Int. J. Mol. Med., t. 56, nr 5, s. 1\u201319, wrz. 2025, doi:https:\/\/doi.org\/10.3892\/ijmm.2025.5628.","DOI":"10.3892\/ijmm.2025.5628"},{"key":"10.1016\/j.intimp.2026.117416_bb0560","doi-asserted-by":"crossref","unstructured":"D. Li et al., \u201eCamel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours\u201d, Nat. Commun., t. 14, nr 1, s. 5920, wrz. 2023, doi:https:\/\/doi.org\/10.1038\/s41467-023-41631-w.","DOI":"10.1038\/s41467-023-41631-w"},{"key":"10.1016\/j.intimp.2026.117416_bb0565","doi-asserted-by":"crossref","unstructured":"Y. J. Xie et al., \u201eNanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice\u201d, Proc. Natl. Acad. Sci. USA, t. 116, nr 16, s. 7624\u20137631, kwi. 2019, doi:https:\/\/doi.org\/10.1073\/pnas.1817147116.","DOI":"10.1073\/pnas.1817147116"},{"key":"10.1016\/j.intimp.2026.117416_bb0570","doi-asserted-by":"crossref","unstructured":"A. R. Eisa, F. Tavassoli Razavi, A. Hoseinzadeh, D. Haghmorad, i R. Baharlou, \u201eNanobody CAR-T cells in cancer: from molecular design to clinical translation\u201d, Biomed. Pharmacother., t. 193, s. 118819, grud. 2025, doi:https:\/\/doi.org\/10.1016\/j.biopha.2025.118819.","DOI":"10.1016\/j.biopha.2025.118819"},{"key":"10.1016\/j.intimp.2026.117416_bb0575","doi-asserted-by":"crossref","unstructured":"S. Guo i X. Xi, \u201eNanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs\u201d, Biomark. Res., t. 13, nr 1, s. 41, mar. 2025, doi:https:\/\/doi.org\/10.1186\/s40364-025-00755-5.","DOI":"10.1186\/s40364-025-00755-5"},{"key":"10.1016\/j.intimp.2026.117416_bb0580","doi-asserted-by":"crossref","unstructured":"Z. Xia et al., \u201eTargeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders\u201d, Nat. Biomed. Eng., t. 8, nr 12, s. 1634\u20131650, pa\u017a. 2024, doi:https:\/\/doi.org\/10.1038\/s41551-024-01258-8.","DOI":"10.1038\/s41551-024-01258-8"},{"key":"10.1016\/j.intimp.2026.117416_bb0585","doi-asserted-by":"crossref","unstructured":"C. M. Hill et al., \u201eImmunologic specificity in glioblastoma: antigen discovery and translational implications\u201d, Neuro-Oncol. Adv., t. 7, nr Supplement_4, s. iv41\u2013iv70, wrz. 2025, doi:https:\/\/doi.org\/10.1093\/noajnl\/vdaf028.","DOI":"10.1093\/noajnl\/vdaf028"},{"key":"10.1016\/j.intimp.2026.117416_bb0590","doi-asserted-by":"crossref","unstructured":"L. Wang et al., \u201eThe evolution of alternative splicing in glioblastoma under therapy\u201d, Genome Biol., t. 22, nr 1, s. 48, grud. 2021, doi:https:\/\/doi.org\/10.1186\/s13059-021-02259-5.","DOI":"10.1186\/s13059-021-02259-5"},{"key":"10.1016\/j.intimp.2026.117416_bb0595","doi-asserted-by":"crossref","unstructured":"R. Li et al., \u201eMathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment\u201d, npj Syst. Biol. Appl., t. 12, nr 1, s. 19, sty. 2026, doi:https:\/\/doi.org\/10.1038\/s41540-025-00642-7.","DOI":"10.1038\/s41540-025-00642-7"},{"key":"10.1016\/j.intimp.2026.117416_bb0600","doi-asserted-by":"crossref","unstructured":"D. W. Kwok et al., \u201eTumour-wide RNA splicing aberrations generate actionable public neoantigens\u201d, Nature, t. 639, nr 8054, s. 463\u2013473, mar. 2025, doi:https:\/\/doi.org\/10.1038\/s41586-024-08552-0.","DOI":"10.1038\/s41586-024-08552-0"},{"key":"10.1016\/j.intimp.2026.117416_bb0605","doi-asserted-by":"crossref","unstructured":"C. Wang, M. Yu, i W. Zhang, \u201eNeoantigen discovery and applications in glioblastoma: an immunotherapy perspective\u201d, Cancer Lett., t. 550, s. 215945, grud. 2022, doi:https:\/\/doi.org\/10.1016\/j.canlet.2022.215945.","DOI":"10.1016\/j.canlet.2022.215945"},{"key":"10.1016\/j.intimp.2026.117416_bb0610","doi-asserted-by":"crossref","unstructured":"M. Poorebrahim, N. Mohammadkhani, R. Mahmoudi, M. Gholizadeh, E. Fakhr, i A. Cid-Arregui, \u201eTCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential\u201d, Cancer Gene Ther., t. 28, nr 6, s. 581\u2013589, cze. 2021, doi:https:\/\/doi.org\/10.1038\/s41417-021-00307-7.","DOI":"10.1038\/s41417-021-00307-7"},{"key":"10.1016\/j.intimp.2026.117416_bb0615","doi-asserted-by":"crossref","unstructured":"M. G. Klatt et al., \u201eA TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies\u201d, Blood, t. 140, nr 8, s. 861\u2013874, sie. 2022, doi:https:\/\/doi.org\/10.1182\/blood.2021012882.","DOI":"10.1182\/blood.2021012882"},{"key":"10.1016\/j.intimp.2026.117416_bb0620","doi-asserted-by":"crossref","unstructured":"P. Vora et al., \u201eThe rational development of CD133-targeting immunotherapies for glioblastoma\u201d, Cell Stem Cell, t. 26, nr 6, s. 832-844.e6, cze. 2020, doi:https:\/\/doi.org\/10.1016\/j.stem.2020.04.008.","DOI":"10.1016\/j.stem.2020.04.008"},{"key":"10.1016\/j.intimp.2026.117416_bb0625","doi-asserted-by":"crossref","unstructured":"R. C. Sterner i R. M. Sterner, \u201eEGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma\u201d, Front. Oncol., t. 14, s. 1434495, wrz. 2024, doi:https:\/\/doi.org\/10.3389\/fonc.2024.1434495.","DOI":"10.3389\/fonc.2024.1434495"},{"key":"10.1016\/j.intimp.2026.117416_bb0630","doi-asserted-by":"crossref","unstructured":"J. Zhong et al., \u201eCircular RNA encoded MET variant promotes glioblastoma tumorigenesis\u201d, Nat. Commun., t. 14, nr 1, s. 4467, lip. 2023, doi:https:\/\/doi.org\/10.1038\/s41467-023-40212-1.","DOI":"10.1038\/s41467-023-40212-1"},{"key":"10.1016\/j.intimp.2026.117416_bb0635","doi-asserted-by":"crossref","unstructured":"H. Kuroda et al., \u201eProstaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma\u201d, Cancer Immunol. Immunother., t. 74, nr 4, s. 136, mar. 2025, doi:https:\/\/doi.org\/10.1007\/s00262-025-03979-4.","DOI":"10.1007\/s00262-025-03979-4"},{"key":"10.1016\/j.intimp.2026.117416_bb0640","doi-asserted-by":"crossref","unstructured":"L. Lertsumitkul et al., \u201eEphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses\u201d, J. Immunother. Cancer, t. 12, nr 8, s. e009486, sie. 2024, doi:https:\/\/doi.org\/10.1136\/jitc-2024-009486.","DOI":"10.1136\/jitc-2024-009486"},{"key":"10.1016\/j.intimp.2026.117416_bb0645","doi-asserted-by":"crossref","unstructured":"S. Peng et al., \u201eSensitive detection and analysis of neoantigen-specific T cell populations from tumors and blood\u201d, Cell Rep., t. 28, nr 10, s. 2728-2738.e7, wrz. 2019, doi:https:\/\/doi.org\/10.1016\/j.celrep.2019.07.106.","DOI":"10.1016\/j.celrep.2019.07.106"},{"key":"10.1016\/j.intimp.2026.117416_bb0650","doi-asserted-by":"crossref","unstructured":"F. Villanueva-Flores, J. I. Sanchez-Villamil, i I. Garcia-Atutxa, \u201eAI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development\u201d, NPJ Vaccines, t. 10, nr 1, s. 207, sie. 2025, doi:https:\/\/doi.org\/10.1038\/s41541-025-01258-y.","DOI":"10.1038\/s41541-025-01258-y"},{"key":"10.1016\/j.intimp.2026.117416_bb0655","doi-asserted-by":"crossref","unstructured":"A.-M. Garrett, S. Lastakchi, i C. McConville, \u201eThe personalisation of glioblastoma treatment using whole exome sequencing: a pilot study\u201d, Genes, t. 11, nr 2, s. 173, lut. 2020, doi:https:\/\/doi.org\/10.3390\/genes11020173.","DOI":"10.3390\/genes11020173"},{"key":"10.1016\/j.intimp.2026.117416_bb0660","doi-asserted-by":"crossref","unstructured":"Q. Lin et al., \u201eIntegrative multi-omic profiling of the neoantigen landscape of glioblastoma for the development of therapeutic vaccines reveals vast heterogeneity in immunogenic signatures\u201d, Front. Oncol., t. 15, s. 1507632, mar. 2025, doi:https:\/\/doi.org\/10.3389\/fonc.2025.1507632.","DOI":"10.3389\/fonc.2025.1507632"},{"key":"10.1016\/j.intimp.2026.117416_bb0665","doi-asserted-by":"crossref","unstructured":"M. Shirzadian, S. Moori, R. Rabbani, i F. Rahbarizadeh, \u201eSynNotch CAR-T cell, when synthetic biology and immunology meet again\u201d, Front. Immunol., t. 16, s. 1545270, kwi. 2025, doi:https:\/\/doi.org\/10.3389\/fimmu.2025.1545270.","DOI":"10.3389\/fimmu.2025.1545270"},{"key":"10.1016\/j.intimp.2026.117416_bb0670","doi-asserted-by":"crossref","unstructured":"P. Pourmasoumi, A. Pourmasoumi, F. Zamani, A. Amini, i S. Shokri, \u201eCAR-T cell therapy in glioblastoma: overcoming immunological barriers and advancing clinical translation\u201d, CMAR, t. Volume 18, s. 1\u201317, lut. 2026, doi:https:\/\/doi.org\/10.2147\/CMAR.S580320.","DOI":"10.2147\/CMAR.S580320"},{"key":"10.1016\/j.intimp.2026.117416_bb0675","doi-asserted-by":"crossref","unstructured":"M. A. Hayat, S. Yu, G. Tao, M. U. Ghani, i J. Hu, \u201eChimeric antigen receptor T cell therapy for glioblastoma: overcoming current barriers and strategies to enhance efficacy for therapeutic implications\u201d, Biochem. Pharmacol., t. 248, s. 117851, cze. 2026, doi:https:\/\/doi.org\/10.1016\/j.bcp.2026.117851.","DOI":"10.1016\/j.bcp.2026.117851"},{"key":"10.1016\/j.intimp.2026.117416_bb0680","doi-asserted-by":"crossref","unstructured":"D. Wang et al., \u201eChlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma\u201d, Sci. Transl. Med., t. 12, nr 533, s. eaaw2672, mar. 2020, doi:https:\/\/doi.org\/10.1126\/scitranslmed.aaw2672.","DOI":"10.1126\/scitranslmed.aaw2672"},{"key":"10.1016\/j.intimp.2026.117416_bb0685","doi-asserted-by":"crossref","unstructured":"M. I. Strecker et al., \u201eAAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma\u201d, OncoImmunology, t. 11, nr 1, s. 2127508, grud. 2022, doi:https:\/\/doi.org\/10.1080\/2162402X.2022.2127508.","DOI":"10.1080\/2162402X.2022.2127508"},{"key":"10.1016\/j.intimp.2026.117416_bb0690","doi-asserted-by":"crossref","unstructured":"J. Huang et al., \u201eApplication of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies\u201d, Fluids Barriers CNS, t. 19, nr 1, s. 38, grud. 2022, doi:https:\/\/doi.org\/10.1186\/s12987-022-00342-y.","DOI":"10.1186\/s12987-022-00342-y"},{"key":"10.1016\/j.intimp.2026.117416_bb0695","doi-asserted-by":"crossref","unstructured":"L. V. B. Fl\u00f8e, M. G. Pedersen, i B. K. M\u00f8ller, \u201eAnimal models in preclinical evaluation of CAR-T cell therapy: advantages and limitations\u201d, Biochim. Biophys. Acta Rev. Cancer, t. 1880, nr 6, s. 189455, lis. 2025, doi:https:\/\/doi.org\/10.1016\/j.bbcan.2025.189455.","DOI":"10.1016\/j.bbcan.2025.189455"},{"key":"10.1016\/j.intimp.2026.117416_bb0700","doi-asserted-by":"crossref","unstructured":"R. A. Vaubel et al., \u201eGenomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma\u201d, Clin. Cancer Res., t. 26, nr 5, s. 1094\u20131104, mar. 2020, doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0909.","DOI":"10.1158\/1078-0432.CCR-19-0909"},{"key":"10.1016\/j.intimp.2026.117416_bb0705","doi-asserted-by":"crossref","unstructured":"F. Jacob, G. Ming, i H. Song, \u201eGeneration and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing\u201d, Nat. Protoc., t. 15, nr 12, s. 4000\u20134033, grud. 2020, doi:https:\/\/doi.org\/10.1038\/s41596-020-0402-9.","DOI":"10.1038\/s41596-020-0402-9"},{"key":"10.1016\/j.intimp.2026.117416_bb0710","doi-asserted-by":"crossref","unstructured":"J. H. Sampson et al., \u201eEGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss\u201d, Clin. Cancer Res., t. 20, nr 4, s. 972\u2013984, lut. 2014, doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0709.","DOI":"10.1158\/1078-0432.CCR-13-0709"},{"key":"10.1016\/j.intimp.2026.117416_bb0715","doi-asserted-by":"crossref","unstructured":"S. Yaacoub et al., \u201eCAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence\u201d, Front. Immunol., t. 16, s. 1596499, cze. 2025, doi:https:\/\/doi.org\/10.3389\/fimmu.2025.1596499.","DOI":"10.3389\/fimmu.2025.1596499"},{"key":"10.1016\/j.intimp.2026.117416_bb0720","doi-asserted-by":"crossref","unstructured":"T. Eckert et al., \u201eImmune resistance in glioblastoma: understanding the barriers to ICI and CAR-T cell therapy\u201d, Cancers, t. 17, nr 3, s. 462, sty. 2025, doi:https:\/\/doi.org\/10.3390\/cancers17030462.","DOI":"10.3390\/cancers17030462"},{"key":"10.1016\/j.intimp.2026.117416_bb0725","doi-asserted-by":"crossref","unstructured":"A. V. Menk et al., \u201e4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses\u201d, J. Exp. Med., t. 215, nr 4, s. 1091\u20131100, kwi. 2018, doi:https:\/\/doi.org\/10.1084\/jem.20171068.","DOI":"10.1084\/jem.20171068"},{"key":"10.1016\/j.intimp.2026.117416_bb0730","doi-asserted-by":"crossref","unstructured":"A. E. Doan et al., \u201eFOXO1 is a master regulator of memory programming in CAR T cells\u201d, Nature, t. 629, nr 8010, s. 211\u2013218, maja 2024, doi:https:\/\/doi.org\/10.1038\/s41586-024-07300-8.","DOI":"10.1038\/s41586-024-07300-8"},{"key":"10.1016\/j.intimp.2026.117416_bb0735","doi-asserted-by":"crossref","unstructured":"N. Jain et al., \u201eDisruption of SUV39H1 -mediated H3K9 methylation sustains CAR T-cell function\u201d, Cancer Discov., t. 14, nr 1, s. 142\u2013157, sty. 2024, doi:https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1319.","DOI":"10.1158\/2159-8290.CD-22-1319"},{"key":"10.1016\/j.intimp.2026.117416_bb0740","doi-asserted-by":"crossref","unstructured":"S. L\u00f3pez-Cobo et al., \u201eSUV39H1 ablation enhances long-term CAR T function in solid tumors\u201d, Cancer Discov., t. 14, nr 1, s. 120\u2013141, sty. 2024, doi:https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1350.","DOI":"10.1158\/2159-8290.CD-22-1350"},{"key":"10.1016\/j.intimp.2026.117416_bb0745","doi-asserted-by":"crossref","unstructured":"W. Czy\u017cewski et al., \u201eCAR-T cell therapy for glioblastoma: advances, challenges, and future directions\u201d, Ann. Med. Surg. 87, nr 9, s. 5743\u20135756, wrz. 2025, doi:https:\/\/doi.org\/10.1097\/MS9.0000000000003607.","DOI":"10.1097\/MS9.0000000000003607"},{"key":"10.1016\/j.intimp.2026.117416_bb0750","doi-asserted-by":"crossref","unstructured":"Y. Sun, Y. Wang, S. Mu, X. Wu, S. Yu, i Z. Wang, \u201eCombining immunotherapy with radiotherapy for glioblastoma: recent advances and challenges\u201d, Front. Oncol., t. 15, s. 1523675, maja 2025, doi:https:\/\/doi.org\/10.3389\/fonc.2025.1523675.","DOI":"10.3389\/fonc.2025.1523675"},{"key":"10.1016\/j.intimp.2026.117416_bb0755","doi-asserted-by":"crossref","unstructured":"Y. Tang et al., \u201eOncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation\u201d, OncoImmunology, t. 15, nr 1, s. 2612377, grud. 2026, doi:https:\/\/doi.org\/10.1080\/2162402X.2025.2612377.","DOI":"10.1080\/2162402X.2025.2612377"},{"key":"10.1016\/j.intimp.2026.117416_bb0760","doi-asserted-by":"crossref","unstructured":"P. Vaughn-Beaucaire, M. J. Choi, O. Liang, i S. E. Lawler, \u201eIntracranial CAR-T cell delivery in glioblastoma patients\u201d, Trends Cancer, t. 10, nr 6, s. 478\u2013480, cze. 2024, doi:https:\/\/doi.org\/10.1016\/j.trecan.2024.05.002.","DOI":"10.1016\/j.trecan.2024.05.002"},{"key":"10.1016\/j.intimp.2026.117416_bb0765","doi-asserted-by":"crossref","unstructured":"S. J. Parvar et al., \u201eConvection-enhanced delivery for brain malignancies: technical parameters, formulation strategies and clinical perspectives\u201d, Adv. Drug Deliv. Rev., t. 224, s. 115657, wrz. 2025, doi:https:\/\/doi.org\/10.1016\/j.addr.2025.115657.","DOI":"10.1016\/j.addr.2025.115657"},{"key":"10.1016\/j.intimp.2026.117416_bb0770","doi-asserted-by":"crossref","unstructured":"S. Smirnov, Y. Zaritsky, S. Silonov, A. Gavrilova, i A. Fonin, \u201eAdvancing CAR-T therapy for solid tumors: from barriers to clinical progress\u201d, Biomolecules, t. 15, nr 10, s. 1407, pa\u017a. 2025, doi:https:\/\/doi.org\/10.3390\/biom15101407.","DOI":"10.3390\/biom15101407"},{"key":"10.1016\/j.intimp.2026.117416_bb0775","doi-asserted-by":"crossref","unstructured":"M. Ijaz et al., \u201eOvercoming barriers in glioblastoma: the potential of CAR T cell immunotherapy\u201d, Theranostics, t. 15, nr 14, s. 7090\u20137126, cze. 2025, doi:https:\/\/doi.org\/10.7150\/thno.114257.","DOI":"10.7150\/thno.114257"},{"key":"10.1016\/j.intimp.2026.117416_bb0780","unstructured":"L. E. Sant'Anna, R. Roy, J. C. Schwab, J. I. Perez, i M. N. Mayalu, CAR T cells from code to clinic: framing modeling approaches with current translational research goals\u201d, 2025, arXiv. doi:10.48550\/ARXIV.2511.03873."},{"key":"10.1016\/j.intimp.2026.117416_bb0785","doi-asserted-by":"crossref","unstructured":"K. T. Roybal et al., \u201ePrecision tumor recognition by T cells with combinatorial antigen-sensing circuits\u201d, Cell, t. 164, nr 4, s. 770\u2013779, lut. 2016, doi:https:\/\/doi.org\/10.1016\/j.cell.2016.01.011.","DOI":"10.1016\/j.cell.2016.01.011"},{"key":"10.1016\/j.intimp.2026.117416_bb0790","doi-asserted-by":"crossref","unstructured":"E. Liu et al., \u201eUse of CAR-transduced natural killer cells in CD19-positive lymphoid tumors\u201d, N. Engl. J. Med., t. 382, nr 6, s. 545\u2013553, lut. 2020, doi:https:\/\/doi.org\/10.1056\/NEJMoa1910607.","DOI":"10.1056\/NEJMoa1910607"},{"key":"10.1016\/j.intimp.2026.117416_bb0795","doi-asserted-by":"crossref","unstructured":"R. Hatae et al., \u201eComparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma model\u201d, Neuro-Oncol. Adv., t. 7, nr 1, s. vdaf074, sty. 2025, doi:https:\/\/doi.org\/10.1093\/noajnl\/vdaf074.","DOI":"10.1093\/noajnl\/vdaf074"},{"key":"10.1016\/j.intimp.2026.117416_bb0800","doi-asserted-by":"crossref","unstructured":"R.-B. Wang et al., \u201eChimeric antigen receptor natural killer T-cell therapy for tumors: promise and progress\u201d, Pathobiology, s. 1\u201313, lut. 2026, doi:https:\/\/doi.org\/10.1159\/000551197.","DOI":"10.1159\/000551197"},{"key":"10.1016\/j.intimp.2026.117416_bb0805","doi-asserted-by":"crossref","unstructured":"Y.-R. Li et al., \u201eAllogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety\u201d, Mol. Ther., t. 33, nr 12, s. 6041\u20136062, grud. 2025, doi:https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.026.","DOI":"10.1016\/j.ymthe.2025.09.026"},{"key":"10.1016\/j.intimp.2026.117416_bb0810","doi-asserted-by":"crossref","unstructured":"K. Riccione, C. M. Suryadevara, D. Snyder, X. Cui, J. H. Sampson, i L. Sanchez-Perez, \u201eGeneration of CAR T cells for adoptive therapy in the context of glioblastoma standard of care\u201d, JoVE, nr 96, s. 52397, lut. 2015, doi:https:\/\/doi.org\/10.3791\/52397.","DOI":"10.3791\/52397"},{"key":"10.1016\/j.intimp.2026.117416_bb0815","doi-asserted-by":"crossref","unstructured":"S. Jeon et al., \u201eMicrofluidic hydroporation platform for effective allogeneic CAR-T cell production and subsequent functional cytotoxicity analysis\u201d, Adv. Mater. Technol., t. 11, nr 10, s. e02210, maja 2026, doi:https:\/\/doi.org\/10.1002\/admt.202502210.","DOI":"10.1002\/admt.202502210"},{"key":"10.1016\/j.intimp.2026.117416_bb0820","doi-asserted-by":"crossref","unstructured":"H. Niu, P. Zhao, i W. Sun, \u201eBiomaterials for chimeric antigen receptor T cell engineering\u201d, Acta Biomater., t. 166, s. 1\u201313, sie. 2023, doi:https:\/\/doi.org\/10.1016\/j.actbio.2023.04.043.","DOI":"10.1016\/j.actbio.2023.04.043"},{"key":"10.1016\/j.intimp.2026.117416_bb0825","doi-asserted-by":"crossref","unstructured":"Z. Wang et al., \u201eNanoparticles-enhanced CAR-T cell therapy: current advances and future directions\u201d, Biomark. Res., t. 14, nr 1, s. 36, lut. 2026, doi:https:\/\/doi.org\/10.1186\/s40364-026-00895-2.","DOI":"10.1186\/s40364-026-00895-2"},{"key":"10.1016\/j.intimp.2026.117416_bb0830","doi-asserted-by":"crossref","unstructured":"Y.-M. Yang et al., \u201eIn vivo CAR-cell therapy: current challenges and emerging therapeutic advances\u201d, Mol. Biomed., t. 7, nr 1, s. 54, kwi. 2026, doi:https:\/\/doi.org\/10.1186\/s43556-026-00447-y.","DOI":"10.1186\/s43556-026-00447-y"},{"key":"10.1016\/j.intimp.2026.117416_bb0835","doi-asserted-by":"crossref","unstructured":"L. Hao, J. Lu, i J. Xue, \u201eIn vivo CAR-T therapy for cancer treatment: mechanisms, technological advances, and clinical translation\u201d, OR, t. 34, nr 5, s. 1\u201310, 2026, doi:10.32604\/or.2026.076420.","DOI":"10.32604\/or.2026.076420"},{"key":"10.1016\/j.intimp.2026.117416_bb0840","doi-asserted-by":"crossref","unstructured":"Y. Xiao et al., \u201eTechnologies for chimeric antigen receptor transgene delivery\u201d, Trends Mol. Med., t. 31, nr 11, s. 1047\u20131064, lis. 2025, doi:https:\/\/doi.org\/10.1016\/j.molmed.2025.05.011.","DOI":"10.1016\/j.molmed.2025.05.011"},{"key":"10.1016\/j.intimp.2026.117416_bb0845","doi-asserted-by":"crossref","unstructured":"Y.-R. Li, Y. Zhu, T. Halladay, i L. Yang, \u201eIn vivo CAR engineering for immunotherapy\u201d, Nat. Rev. Immunol., t. 25, nr 10, s. 725\u2013744, pa\u017a. 2025, doi:https:\/\/doi.org\/10.1038\/s41577-025-01174-1.","DOI":"10.1038\/s41577-025-01174-1"},{"key":"10.1016\/j.intimp.2026.117416_bb0850","doi-asserted-by":"crossref","unstructured":"T. Tykocki, \u201eDiffuse intrinsic pontine glioma and chimeric antigen receptor T-cell therapy: an emerging frontier\u201d, World Neurosurg., t. 194, s. 123579, lut. 2025, doi:https:\/\/doi.org\/10.1016\/j.wneu.2024.123579.","DOI":"10.1016\/j.wneu.2024.123579"},{"key":"10.1016\/j.intimp.2026.117416_bb0855","doi-asserted-by":"crossref","unstructured":"S. Pandit, P. Agarwalla, F. Song, A. Jansson, G. Dotti, i Y. Brudno, \u201eImplantable CAR T cell factories enhance solid tumor treatment\u201d, Biomaterials, t. 308, s. 122580, lip. 2024, doi:https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122580.","DOI":"10.1016\/j.biomaterials.2024.122580"},{"key":"10.1016\/j.intimp.2026.117416_bb0860","doi-asserted-by":"crossref","unstructured":"C. Bayona, T. Ran\u0111elovi\u0107, i I. Ochoa, \u201eTumor microenvironment in glioblastoma: the central role of the hypoxic\u2013necrotic core\u201d, Cancer Lett., t. 639, s. 218216, lut. 2026, doi:https:\/\/doi.org\/10.1016\/j.canlet.2025.218216.","DOI":"10.1016\/j.canlet.2025.218216"},{"key":"10.1016\/j.intimp.2026.117416_bb0865","doi-asserted-by":"crossref","unstructured":"J. Liu et al., \u201eEndogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry\u201d, J. Neuro-Oncol., t. 177, nr 1, s. 50, mar. 2026, doi:https:\/\/doi.org\/10.1007\/s11060-026-05497-4.","DOI":"10.1007\/s11060-026-05497-4"},{"key":"10.1016\/j.intimp.2026.117416_bb0870","doi-asserted-by":"crossref","unstructured":"M. Szafra\u0144ska-\u0141\u0119czycka, Z. Szyma\u0144ska, M. J. Piotrowska, M. Bodnar, i U. Fory\u015b, \u201eCAR-T cell therapy for glioblastoma: insight from mathematical modeling\u201d, Front. Immunol., t. 16, s. 1563829, cze. 2025, doi:https:\/\/doi.org\/10.3389\/fimmu.2025.1563829.","DOI":"10.3389\/fimmu.2025.1563829"},{"key":"10.1016\/j.intimp.2026.117416_bb0875","doi-asserted-by":"crossref","unstructured":"J. Bria et al., \u201eRecurrent limitations of CAR-T therapy in gliomas: evidence from preclinical and phase I clinical studies\u201d, Int. J. Mol. Sci., t. 26, nr 23, s. 11435, lis. 2025, doi:https:\/\/doi.org\/10.3390\/ijms262311435.","DOI":"10.3390\/ijms262311435"},{"key":"10.1016\/j.intimp.2026.117416_bb0880","doi-asserted-by":"crossref","unstructured":"A. Winnifrith, C. Outeiral, i B. L. Hie, \u201eGenerative artificial intelligence for de novo protein design\u201d, Curr. Opin. Struct. Biol., t. 86, s. 102794, cze. 2024, doi:https:\/\/doi.org\/10.1016\/j.sbi.2024.102794.","DOI":"10.1016\/j.sbi.2024.102794"},{"key":"10.1016\/j.intimp.2026.117416_bb0885","doi-asserted-by":"crossref","unstructured":"L. Cao et al., \u201eDesign of protein-binding proteins from the target structure alone\u201d, Nature, t. 605, nr 7910, s. 551\u2013560, maja 2022, doi:https:\/\/doi.org\/10.1038\/s41586-022-04654-9.","DOI":"10.1038\/s41586-022-04654-9"},{"key":"10.1016\/j.intimp.2026.117416_bb0890","doi-asserted-by":"crossref","unstructured":"B. Chen et al., \u201eIn silico clinical trials in drug development: a systematic review\u201d, Ther. Innov. Regul. Sci., t. 60, nr 2, s. 423\u2013439, mar. 2026, doi:https:\/\/doi.org\/10.1007\/s43441-025-00893-w.","DOI":"10.1007\/s43441-025-00893-w"},{"key":"10.1016\/j.intimp.2026.117416_bb0895","doi-asserted-by":"crossref","unstructured":"P. Moingeon, M. Chenel, C. Rousseau, E. Voisin, i M. Guedj, \u201eVirtual patients, digital twins and causal disease models: paving the ground for in silico clinical trials\u201d, Drug Discov. Today, t. 28, nr 7, s. 103605, lip. 2023, doi:https:\/\/doi.org\/10.1016\/j.drudis.2023.103605.","DOI":"10.1016\/j.drudis.2023.103605"},{"key":"10.1016\/j.intimp.2026.117416_bb0900","doi-asserted-by":"crossref","unstructured":"N. S. H. Al Shaer et al., \u201eCAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead\u201d, Front. Immunol., t. 17, s. 1796675, kwi. 2026, doi:https:\/\/doi.org\/10.3389\/fimmu.2026.1796675.","DOI":"10.3389\/fimmu.2026.1796675"},{"key":"10.1016\/j.intimp.2026.117416_bb0905","doi-asserted-by":"crossref","unstructured":"A. M. E. Abdalla, Y. Miao, Y. A. Taha, N. Meng, i C. Ouyang, \u201eStrategies of AI -driven CAR -T cell therapy towards solid tumours\u201d, Immunology, s. imm.70124, lut. 2026, doi:https:\/\/doi.org\/10.1111\/imm.70124.","DOI":"10.1111\/imm.70124"},{"key":"10.1016\/j.intimp.2026.117416_bb0910","doi-asserted-by":"crossref","unstructured":"G. Putignano, S. Ruip\u00e9rez-Campillo, Z. Yuan, J. Millet, i S. Guerrero-Aspizua, \u201eMathematical models and computational approaches in CAR-T therapeutics\u201d, Front. Immunol., t. 16, s. 1581210, sie. 2025, doi:https:\/\/doi.org\/10.3389\/fimmu.2025.1581210.","DOI":"10.3389\/fimmu.2025.1581210"},{"key":"10.1016\/j.intimp.2026.117416_bb0915","doi-asserted-by":"crossref","unstructured":"A. Murias-Closas, C. Prats, G. Calvo, D. L\u00f3pez-Codina, i E. Olesti, \u201eComputational modelling of CAR T-cell therapy: from cellular kinetics to patient-level predictions\u201d, EBioMedicine, t. 113, s. 105597, mar. 2025, doi:https:\/\/doi.org\/10.1016\/j.ebiom.2025.105597.","DOI":"10.1016\/j.ebiom.2025.105597"},{"key":"10.1016\/j.intimp.2026.117416_bb0920","doi-asserted-by":"crossref","unstructured":"S. J. Bagley et al., \u201eIntrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results\u201d, Nat. Med., t. 30, nr 5, s. 1320\u20131329, maja 2024, doi:https:\/\/doi.org\/10.1038\/s41591-024-02893-z.","DOI":"10.1038\/s41591-024-02893-z"},{"key":"10.1016\/j.intimp.2026.117416_bb0925","doi-asserted-by":"crossref","unstructured":"C. E. Brown et al., \u201eLocoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial\u201d, Nat. Med., t. 30, nr 4, s. 1001\u20131012, kwi. 2024, doi:https:\/\/doi.org\/10.1038\/s41591-024-02875-1.","DOI":"10.1038\/s41591-024-02875-1"},{"key":"10.1016\/j.intimp.2026.117416_bb0930","doi-asserted-by":"crossref","unstructured":"J. D. Clubb et al., \u201eArmored chimeric antigen receptor T-cell therapy targets antigen-heterogeneous glioma\u201d, Cancer Res., t. 86, nr 15, s. 3781\u20133800, sie. 2026, doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-26-1515.","DOI":"10.1158\/0008-5472.CAN-26-1515"},{"key":"10.1016\/j.intimp.2026.117416_bb0935","doi-asserted-by":"crossref","unstructured":"S. Shen et al., \u201eIL-12-secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma\u201d, J. Immunother. Cancer, t. 14, nr 3, s. e012532, mar. 2026, doi:https:\/\/doi.org\/10.1136\/jitc-2025-012532.","DOI":"10.1136\/jitc-2025-012532"},{"key":"10.1016\/j.intimp.2026.117416_bb0940","doi-asserted-by":"crossref","unstructured":"M. Shahzadi et al., \u201eArtificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives\u201d, Ther. Adv. Vaccines Immunother., t. 12, s. 25151355241305856, sty. 2024, doi:https:\/\/doi.org\/10.1177\/25151355241305856.","DOI":"10.1177\/25151355241305856"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926012634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926012634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:59:43Z","timestamp":1790272783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926012634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":188,"alternative-id":["S1567576926012634"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117416","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering next-generation CAR-T cells for glioblastoma treatment: a review of innovations in receptor design, antigen targeting, and therapeutic persistence","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117416"}}